Haptoglobins

Related Subjects: |Heme |Globins |Haptoglobins |Myoglobin |Cardiac Troponins |Transferrin |Iodine |Cell Adhesion Molecules |B Lymphocytes |Anatomy of the Glomerulus

🩸 Haptoglobin (Hp) is an acute-phase plasma glycoprotein produced mainly by the liver. Its primary role is to bind free haemoglobin (Hb) released during intravascular haemolysis, forming a stable Hp-Hb complex that prevents Hb-induced oxidative damage (via heme/iron) and facilitates safe clearance by macrophages via the CD163 receptor. This protects kidneys, vessels, and tissues from free Hb toxicity.

🧬 Structure of Haptoglobin

• Basic unit: Tetramer = 2 α chains + 2 β chains (linked by disulfide bonds).
• β chain: ~40–45 kDa; contains the Hb-binding site (one per β; binds αβ Hb dimer).
• α chain: Variable (α1 ~9 kDa, α2 ~16 kDa due to duplication).
• Phenotypes (genetic polymorphisms):
  • Hp1-1: Homozygous α1/α1 → smallest tetramer (~86 kDa).
  • Hp2-1: Heterozygous α1/α2 → intermediate multimers.
  • Hp2-2: Homozygous α2/α2 → large polymeric forms (up to >400 kDa).
• Glycosylation: Multiple N- and O-linked glycans → affects clearance and function.

⚙️ Functions of Haptoglobin

• Haemoglobin scavenging 🛡️: Binds free Hb dimers (αβ) with very high affinity (Kd ~10⁻¹² M) → prevents heme release, oxidative stress, nitric oxide scavenging, renal tubular damage.
• Complex clearance ♻️: Hp-Hb complex recognised by CD163 (macrophage scavenger receptor) → endocytosis → lysosomal degradation → heme catabolised by heme oxygenase-1 → iron recycled via ferroportin.
• Antioxidant & cytoprotective 🧪: Limits free Hb toxicity (lipid peroxidation, endothelial dysfunction); Hp2-2 less efficient binding/clearance → higher CVD risk.
• Acute-phase reactant 🔥: ↑ synthesis in inflammation/infection (IL-6 mediated) → non-specific host defence (iron sequestration from pathogens).

📈 Regulation of Haptoglobin Levels

• Haemolysis 📉: Rapid consumption → undetectable levels in significant intravascular haemolysis (e.g., transfusion reactions, AIHA, PNH).
• Acute-phase response 📈: IL-6 → ↑ transcription (liver) → levels rise 3–8× within 24–48 h (infection, trauma, malignancy).
• Hepcidin–iron axis: Inflammation ↑ hepcidin → ↓ iron availability → indirect effect on Hp.
• Liver disease 📉: ↓ synthesis in cirrhosis/advanced failure → low baseline levels.
• Genetic factors: Hp phenotype influences baseline levels and binding efficiency (Hp2-2 often lower functional capacity).

🩺 Clinical Significance & Lab Interpretation

• Lab testing: Immunoturbidimetric assay (normal range ~0.3–2.0 g/L; often reported as <0.1 g/L in haemolysis).
• Phenotyping: Gel electrophoresis or PCR (Hp1/Hp2 alleles); useful in CVD risk stratification, research.

Teaching Point 🩺 Haptoglobin = plasma Hb scavenger → binds free Hb during intravascular haemolysis → CD163-mediated clearance → protects from oxidative/renal toxicity. Low/undetectable Hp = sensitive marker of intravascular haemolysis (AIHA, PNH, transfusion reaction). High Hp = acute-phase response (inflammation, infection). Phenotypes: Hp2-2 → poorer Hb binding → ↑ risk of CVD/diabetes complications. Always interpret with haemolysis markers (LDH, indirect bilirubin, reticulocytes) and acute-phase markers (CRP).

📚 References (Feb 2026)

• Smith A & Hunt RC. Haptoglobin structure & function. Antioxid Redox Signal 2025 update.
• WHO/CDC Anaemia Diagnostic Guidelines (2024–2026): Hp in haemolysis workup.
• Langlois MR et al. Hp phenotypes & CVD risk. Clin Chem Lab Med 2025.
• Recent: Hp2-2 in diabetic nephropathy (Diabetes Care 2026).